OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Performance

Shares of NASDAQ OPGN opened at $2.70 on Tuesday. The stock’s fifty day moving average is $1.29 and its 200 day moving average is $1.44. OpGen has a 52 week low of $0.53 and a 52 week high of $9.90.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.